KHERION
LIVE

Serial Number

79267807

Owner

Kherion Technology Limited

Attorney

John P. McCormick

Filing Date

Apr 4, 2019

Add to watchlist:

No watchlists yet
View on USPTO

KHERION Trademark

Serial Number: 79267807 • Registration: 6413425

KHERION is a trademark filed by Kherion Technology Limited on April 4, 2019. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Kherion Technology Limited

c/o St John's Innovation Centre Ltd

Entity Type: 99

Trademark Details

Filing Date

April 4, 2019

Registration Date

July 13, 2021

Published for Opposition

November 24, 2020

Goods & Services

Electronic data in recorded form and downloadable electronic publications in the nature of reports, articles, e-books and e-zines relating to enzymes, vaccines, pharmaceuticals and pharmaceutical, medical and veterinary preparations and substances

Pharmaceutical preparations for the treatment and prevention of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, cardiovascular diseases or disorders, metabolic diseases or disorders, inflammation, cancer, and diabetes; pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical, medical and veterinary preparations and substances for the treatment and prevention of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, cardiovascular diseases or disorders, metabolic diseases or disorders, inflammation, cancer, and diabetes; pharmaceutical, medical and veterinary preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases or disorders; enzymes for medical and veterinary purposes; vaccines; diagnostic agents, reagents, preparations and substances for pharmaceutical, medical and veterinary purposes; Biological preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders, namely, blood fraction proteins; Biological preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases or disorders, namely, human plasma proteins; Biological preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders, namely, animal plasma proteins; gene regulatory proteins for medical use; Biological preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders, namely, antibodies; antibody receptors for medical use; antigens for medical use; antigen receptors for medical use; sanitary preparations for medical and veterinary purposes; preparations for destroying vermin; fungicides, herbicides; molecular components and complexes for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders

Scientific and technological services and research and design relating thereto relating to enzymes, vaccines, pharmaceuticals and pharmaceutical, medical and veterinary preparations and substances; research in the field of molecular biology; pharmaceutical, medical and veterinary research; industrial analysis in the biological, pharmaceutical, medical, and veterinary fields; industrial research services in the fields of pharmaceuticals, medicine and science; research, development, testing and evaluation of pharmaceuticals and of pharmaceutical, medical and veterinary preparations and substances; research, development, testing and evaluation of enzymes and of diagnostic agents, reagents, preparations and substances for pharmaceutical, medical and veterinary purposes; provision of information and consultancy in relation to any of the aforesaid services

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 15, 2021 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Oct 24, 2021 FICS
FINAL DISPOSITION PROCESSED
Oct 23, 2021 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 13, 2021 FICR
REGISTERED-PRINCIPAL REGISTER
Jul 13, 2021 R.PR
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Jun 3, 2021 ETOP
LIMITATION FROM THE IB - REQUEST EXAM REVIEW
Apr 27, 2021 LIME
LIMITATION OF GOODS RECEIVED FROM IB
Apr 17, 2021 LIMG
NEW REPRESENTATIVE AT IB RECEIVED
Apr 17, 2021 NREP
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Mar 13, 2021 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 24, 2021 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Feb 24, 2021 OPNR
NOTIFICATION PROCESSED BY IB
Dec 12, 2020 GPNX
EXTENSION OF TIME TO OPPOSE RECEIVED
Nov 24, 2020 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 24, 2020 NPUB
PUBLISHED FOR OPPOSITION
Nov 24, 2020 PUBO
NOTIFICATION PROCESSED BY IB
Nov 21, 2020 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 4, 2020 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Nov 4, 2020 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 4, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 19, 2020 CNSA
EXAMINER'S AMENDMENT ENTERED
Oct 16, 2020 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 16, 2020 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 16, 2020 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 16, 2020 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
May 27, 2020 GNFN
FINAL REFUSAL E-MAILED
May 27, 2020 GNFR
FINAL REFUSAL WRITTEN
May 27, 2020 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 28, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 28, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 28, 2020 TROA
REFUSAL PROCESSED BY IB
Nov 22, 2019 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Nov 2, 2019 RFCS
REFUSAL PROCESSED BY MPU
Nov 2, 2019 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Oct 16, 2019 RFCR
NON-FINAL ACTION WRITTEN
Oct 15, 2019 CNRT
APPLICATION FILING RECEIPT MAILED
Oct 5, 2019 MAFR
ASSIGNED TO EXAMINER
Oct 1, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 1, 2019 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 19, 2019 REPR